drugset / Trial / NCT00502970

Short Course of Interferon Treatment in Patients With HCV Infection

NCT00502970

Phase 4 Completed 150 enrolled Aga Khan University Getz Pharma · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine if a shorter course of interferon and ribavirin therapy will be sufficient in carefully selected patients with chronic hepatitis C virus genotype 3 infection, as compared to the standard length of treatment of 6 months.

Timeline

Start
2004-05
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 800 mg
Subject Ribavirin Small molecule 1200 mg
Subject interferon alfa Protein / enzyme biologic 3e+06 iu Subcutaneous